Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
AstraZeneca
Harvard Business School
Johnson and Johnson
Express Scripts

Last Updated: February 7, 2023

CLINICAL TRIALS PROFILE FOR ADREVIEW


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Adreview

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00730444 ↗ Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma Approved for marketing GE Healthcare 1969-12-31 GE Healthcare has recently submitted a New Drug Application (NDA) for Iobenguane I 123 Injection ([123I]mIBG (AdreView)) as a diagnostic nuclear imaging agent for the detection of primary or metastatic neuroblastoma and pheochromocytoma. The present protocol establishes an Expanded Access program to provide AdreView to pediatric medical centers and hospitals that treat neuroblastoma patients. AdreView will be provided for use in diagnostic assessment of patients with known or suspected neuroblastoma for whom there is an appropriate clinical indication for [123I]mIBG imaging.
NCT01522378 ↗ Cardiac Resynchronization and Iodine Meta-Iodobenzylguanidine (MIBG) Imaging Terminated GE Healthcare Phase 1 2012-02-01 Subjects were recruited if their healthcare provider decided that they needed treatment with a special Internal Cardiac Defibrillator (ICD) called a biventricular ICD. The investigators did this study to see if part of the nerve organ, called the sympathetic nervous system, may be responsible for the improvement seen in patients that receive biventricular pacing. The investigators had three ways to measure sympathetic nervous activity: 1) by using a special blood sample, 2) by monitoring heart rhythm, and 3) by performing a special heart scan.
NCT01522378 ↗ Cardiac Resynchronization and Iodine Meta-Iodobenzylguanidine (MIBG) Imaging Terminated Mayo Clinic Phase 1 2012-02-01 Subjects were recruited if their healthcare provider decided that they needed treatment with a special Internal Cardiac Defibrillator (ICD) called a biventricular ICD. The investigators did this study to see if part of the nerve organ, called the sympathetic nervous system, may be responsible for the improvement seen in patients that receive biventricular pacing. The investigators had three ways to measure sympathetic nervous activity: 1) by using a special blood sample, 2) by monitoring heart rhythm, and 3) by performing a special heart scan.
NCT01868841 ↗ 123-I mIBG (AdreView) Heart-to-Mediastinal (H/M) Ratio and SPECT Imaging on a Small Field of View-High Efficiency Cardiac SPECT System Completed GE Healthcare Phase 4 2013-12-01 The purpose of this study is to demonstrate correlation of the H/M ratio of AdreView when derived from a large field of view Anger SPECT system and from a small field of view high sensitivity (CZT) SPECT system.
NCT01868841 ↗ 123-I mIBG (AdreView) Heart-to-Mediastinal (H/M) Ratio and SPECT Imaging on a Small Field of View-High Efficiency Cardiac SPECT System Completed Timothy M. Bateman Phase 4 2013-12-01 The purpose of this study is to demonstrate correlation of the H/M ratio of AdreView when derived from a large field of view Anger SPECT system and from a small field of view high sensitivity (CZT) SPECT system.
NCT01936649 ↗ Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView. Completed H2O Clinical LLC Phase 4 2013-08-01 The aim of the study was to assess the reproducibility of quantitative measurements of myocardial uptake of Iobenguane I 123 on planar and single photon emission computed tomography (SPECT) imaging following intravenous (i.v.) administration of AdreView. Efficacy was assessed based upon the absolute differences between quantitative analyses of imaging data on 2 scans performed 5 to 14 days apart.
NCT01936649 ↗ Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView. Completed Quintiles, Inc. Phase 4 2013-08-01 The aim of the study was to assess the reproducibility of quantitative measurements of myocardial uptake of Iobenguane I 123 on planar and single photon emission computed tomography (SPECT) imaging following intravenous (i.v.) administration of AdreView. Efficacy was assessed based upon the absolute differences between quantitative analyses of imaging data on 2 scans performed 5 to 14 days apart.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Adreview

Condition Name

Condition Name for Adreview
Intervention Trials
Heart Failure 3
Mild Cognitive Impairment 1
Neuroblastoma 1
Parkinsonism 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Adreview
Intervention Trials
Heart Failure 4
Coronary Disease 1
REM Sleep Behavior Disorder 1
Coronary Artery Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Adreview

Trials by Country

Trials by Country for Adreview
Location Trials
United States 19
Canada 5
Germany 1
Netherlands 1
France 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Adreview
Location Trials
Minnesota 2
New Jersey 2
North Carolina 1
Texas 1
Missouri 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Adreview

Clinical Trial Phase

Clinical Trial Phase for Adreview
Clinical Trial Phase Trials
Phase 4 3
Phase 3 2
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Adreview
Clinical Trial Phase Trials
Completed 3
Terminated 2
Approved for marketing 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Adreview

Sponsor Name

Sponsor Name for Adreview
Sponsor Trials
GE Healthcare 6
Mayo Clinic 2
H2O Clinical LLC 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Adreview
Sponsor Trials
Industry 11
Other 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
McKesson
Medtronic
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.